Pyrotinib
- Generic Name
- Pyrotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 59
- Registration Number
- NCT03772353
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
- Conditions
- Breast CancerBreast DiseasesNeoplasm, Breast
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03756064
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT03735966
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT03691051
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 355
- Registration Number
- NCT03588091
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Huai'an First People's Hospital, Huaian, Jiangsu, China
🇨🇳The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China
Phase II Umbrella Study Directed by Next Generation Sequencing
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Conditions
- HER2 Gene MutationBreast Cancer
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 14
- Registration Number
- NCT03412383
- Locations
- 🇨🇳
Fei Ma, Beijing, Beijing, China
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT03080805
- Locations
- 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 279
- Registration Number
- NCT02973737
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT02834936
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳HR-BLTN-II-NSCLC Investigational Site, Zhengzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.